Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 9615
Label UNT Conférences

le (17m44s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARGCVCT: Speaker: Faiez ZANNAD, Nancy, FRAESC Working group in Pharmacology and Drug Therapy : Speaker: Christian TORP-PEDERSEN, Copenhagen, DENAbstract : L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 ESC Working group on cardiovascular pharmacology and drug therapyInternational Society of Cardiovascular Pharmacotherapy (ISCP)CardioVascular Clinical Trialists (CVCT)Joint sessionPERSONALIZED CARDIOVASCULAR MEDICINE AND DRUG DEVELOPMENT: TIME FOR A NEW TRIAL PARADIGMChairpersons: Juan Carlos KASKI, London, GBR ...
Voir la vidéo
Label UNT Conférences

le (41m46s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicineHow future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARGCVCT: Speaker: Faiez ZANNAD, Nancy, FRAESC Working group in Pharmacology and Drug Therapy : Speaker: Christian TORP-PEDERSEN, Copenhagen, DENAbstract : Omics research and system biology. Keys for future personalized medicineHow future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global ...
Voir la vidéo
Label UNT Conférences

le (36m52s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkersSpeaker: Stefan BLANKENBERG, Hamburg, GERAbstract : The role of biomarkersL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 ESC Working group on cardiovascular pharmacology and drug therapyInternational Society of Cardiovascular Pharmacotherapy (ISCP)CardioVascular Clinical Trialists (CVCT)Joint sessionPERSONALIZED CARDIOVASCULAR MEDICINE AND DRUG DEVELOPMENT: TIME FOR A NEW TRIAL PARADIGMChairpersons: Juan Carlos KASKI, London, GBR - Bertram PITT, Ann Arbor, USA - Luis RUILOPE, Madrid, ESP- “Drugs, in general, act not on ...
Voir la vidéo
Label UNT Conférences

le (4m38s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpointsSpeaker: John JARCHO, Boston, USA, NEJMDiscussant: Rita REDBERG, San Francisco, USA, Arch Intern MedAbstract : Biomarker studies have proliferated widely, but the actual impact of most such studies on the practice of medicine is modest. One major underlying problem is a lack of clarity (on the part of both investigators and readers) about what biomarker data can be expected to contribute. In many cases, studies merely demonstrate a statistical association between a putative biomarker and a clinical correlate, but the implications of this association are not made explicit. In ...
Voir la vidéo
Label UNT Conférences

le (16m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?Speaker: Jim JANUZZI, Boston, USADiscussant: James SNIDER, Critical Diagnostics, USAAbstract : How should Diagnostic and Prognostic Markers BeStudied? The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach with which these potentially important tests have ...
Voir la vidéo
Label UNT Conférences

le (14m51s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel markerSpeaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : Best statistical methods for evaluating the merits of a novel markerThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach ...
Voir la vidéo
Label UNT Conférences

le (7m59s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel markerSpeaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : Best statistical methods for evaluating the merits of a novel markerThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach ...
Voir la vidéo
Label UNT Conférences

le (10m1s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).Speaker: Stefan BLANKENBERG, Hamburg, GERDiscussant: Nancy GELLER, Bethesda, USAAbstract : debate : Best statistical methods for evaluating the merits of a novel marker (debates).The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come ...
Voir la vidéo
Label UNT Conférences

le (17m30s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresSpeaker: Michael FELKER, Durham, USAAbstract : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measuresThe measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear ...
Voir la vidéo
Label UNT Conférences

le (4m2s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement establishing rules for biomarker studies?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?John JARCHO, Boston, USA, NEJMRita REDBERG, San Francisco, USA, Arch Intern MedJoseph LOSCALZO, Boston, USA, CirculationJagat NARULA, New York, USA, JACC imagingMona FIUZAT, Durham, USA, JACC-HFJohn CLELAND, Hull, GBR, Former Eur J Heart FailureAbstract : Debate led by Journal Editors: There are too many studies and the quality is variable.Should there be a position statement establishing rules for biomarker studies?The measurement of biomarkers for diagnosis and prognosis ...
Voir la vidéo

 
FMSH
 
Facebook Twitter
Mon Compte